Cognition Therapeutics, Inc.(CGTX)Earnings, Financials & Key Ratios

Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and delusion benefits.

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -

PURCHASE, N.Y., June 16, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for patent application 19/563,468.